Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 588 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: First-line Chemotherapy Clear all
Completed Phase 1 Interventional

Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

NCT03177291
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Lung Cancer, Squamous Cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung
Interventions
Pirfenidone, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Sep 2, 2026, 6:33 AM EDT
Withdrawn Phase 4 Interventional

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases

NCT00510627
View directory record Official record
Conditions
Metastatic Liver Cancer, Secondary Liver Cancer, Liver Neoplasm
Interventions
Radiofrequency Ablation (RFA), Chemotherapy
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 2, 2026, 6:33 AM EDT
Active, not recruiting Phase 2 Interventional

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

NCT04858269
View directory record Official record
Conditions
Head Neck Cancer, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma
Interventions
Pembrolizumab, Carboplatin, Paclitaxel
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Active, not recruiting Phase 2 Interventional

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

NCT05329766
View directory record Official record
Conditions
Gastrointestinal Tract Malignancies
Interventions
Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
16
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Withdrawn Phase 2 Interventional

Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma

NCT05107427
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
MRx0518, Avelumab 20 mg/mL Intravenous Solution (IV)
Drug · Biological
Lead sponsor
4D pharma plc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Irvine, California • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 2, 2026, 6:33 AM EDT
Recruiting Phase 3 Interventional

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531
View directory record Official record
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent), 5-fluorouracil (5-FU), Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
37
States / cities
Birmingham, Alabama • Bakersfield, California • Cerritos, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 3 Interventional

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

NCT03748134
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Sintilimab, Cisplatin, Paclitaxel, Fluorouracil, Placebo
Biological · Drug
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
7
States / cities
Anaheim, California • Orange, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Sep 2, 2026, 6:33 AM EDT
Active, not recruiting Phase 1 Interventional

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

NCT05614102
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY2965501, Pembrolizumab, Platinum-based Chemotherapy
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Terminated Phase 3 Interventional Results available

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

NCT00968968
View directory record Official record
Conditions
Cancer
Interventions
Lapatinib, Trastuzumab
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
112
States / cities
Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00266110
View directory record Official record
Conditions
Breast Cancer
Interventions
sargramostim, therapeutic autologous dendritic cells, trastuzumab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 2, 2026, 6:33 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Calderasib, Pembrolizumab (+) Berahyaluronidase alfa, Pemetrexed, Cisplatin, Carboplatin
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
12
States / cities
Birmingham, Alabama • Farmington, Connecticut • Stamford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Terminated Phase 1 Interventional Results available

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

NCT04422210
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Venetoclax, Atezolizumab, Carboplatin, Etoposide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 1 Interventional

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

NCT04085315
View directory record Official record
Conditions
Lung Cancer Metastatic, EGFR Gene Mutation
Interventions
Osimertinib, Alisertib
Drug
Lead sponsor
Collin Blakely
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Terminated Phase 1 Interventional Results available

Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy

NCT00424840
View directory record Official record
Conditions
Lung Cancer
Interventions
Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Bortezomib 1.8 mg/m2, Carboplatin AUC 6, Bevacizumab, Taxotere
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 2, 2026, 6:33 AM EDT
Terminated Phase 3 Interventional

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

NCT03520686
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
NAI + Pembrolizumab, NAI + Nivolumab + Ipilimumab, NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI, Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI, Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI, Carboplatin + Nab-paclitaxel + Atezolizumab + NAI, Pembrolizumab, Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab, Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab, Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab, Carboplatin and Nab-paclitaxel plus Atezolizumab, Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
31
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00866697
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Pazopanib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
35
States / cities
Anaheim, California • Baldwin Park, California • Bellflower, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 2, 2026, 6:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

NCT07444541
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ANO31905, Nanoparticle Albumin-Bound Paclitaxel, Gemcitabine
Biological · Drug
Lead sponsor
Anova Innovation Limited
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 2 Interventional Results available

Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)

NCT01845805
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
oral azacitidine, Observation
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 2, 2026, 6:33 AM EDT
Terminated No phase listed Observational

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

NCT04698681
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Mutation, NFE2L2 Gene Mutation
Interventions
Not listed
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Sep 2, 2026, 6:33 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

NCT03093922
View directory record Official record
Conditions
Urothelial Carcinoma, Locally Advanced, Unresectable
Interventions
Atezolizumab, Gemcitabine, Cisplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
9
States / cities
Chicago, Illinois • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Active, not recruiting Phase 3 Interventional

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
37
States / cities
Hot Springs, Arkansas • Springdale, Arkansas • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC

NCT00517595
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Pemetrexed and Gemcitabine plus Bevacizumab
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
65 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
Waterbury, Connecticut • Augusta, Georgia • Macon, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2012 · Synced Sep 2, 2026, 6:33 AM EDT
Terminated Phase 3 Interventional

Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer

NCT00070122
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
oxaliplatin, leucovorin calcium, capecitabine, bevacizumab, fluorouracil, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Sep 2, 2026, 6:33 AM EDT
Completed No phase listed Observational

Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer

NCT01471483
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
geriatric assessment and telephone call from nurse, geriatric assessment and no call from nurse
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
3
States / cities
Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Sep 2, 2026, 6:33 AM EDT